Phenotypic Characterization and Isolation of Myeloid-Derived Suppressor Cells.
MDSC
chronic inflammation
flow cytometry
immunofluorescence imaging
immunosuppression
inflammatory mouse model
myeloid-derived suppressor cells
patient MDSC
Journal
Current protocols
ISSN: 2691-1299
Titre abrégé: Curr Protoc
Pays: United States
ID NLM: 101773894
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
entrez:
10
10
2022
pubmed:
11
10
2022
medline:
13
10
2022
Statut:
ppublish
Résumé
Myeloid-derived suppressor cells (MDSCs) are heterogenous populations of immature myeloid cells that can be divided into two main subpopulations, polymorphonuclear (PMN) MDSCs and monocytic (M) MDSCs. These cells accumulate during chronic inflammation and induce immunosuppression evident in an array of pathologies such as cancer, inflammatory bowel disease, and infectious and autoimmune diseases. Herein, we describe methods to isolate and characterize MDSCs from various murine tissue, as well as to phenotype blood-derived MDSCs from patients. The protocols describe methods for isolation of total MDSCs and their subpopulations, for characterization, and for evaluation of their distribution within tissue, as well as for assessing their maturation stage by flow cytometry, immunofluorescence analyses, and Giemsa staining. © 2022 The Authors. Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1: Single-cell suspension generation from different tissue Alternate Protocol 1: Single-cell suspension generation from subcutaneous melanoma tumors Basic Protocol 2: Characterization of MDSC phenotype Basic Protocol 3: Cell separation using magnetic beads: Separating pan-MDSCs or PMN-MDSC and M-MDSC subpopulations Alternate Protocol 2: Staining and preparing MDSCs for sorting Support Protocol: PMN-MDSC and M-MDSC gating strategy in mouse Basic Protocol 4: Immunofluorescence analysis of MDSCs Basic Protocol 5: Handling human blood samples and characterizing human MDSCs Alternate Protocol 3: Flow cytometry staining of thawed human whole blood samples.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e561Subventions
Organisme : Israel Science Foundation
Organisme : Israeli Ministry of Health
Organisme : Israel Cancer Research Fund
Organisme : the Israel Ministry of Science and Technology
Organisme : the Gross Foundation
Organisme : the Bruce and Baila Waldholtz funds
Organisme : the Joseph and Matilda Melnick Funds
Informations de copyright
© 2022 The Authors. Current Protocols published by Wiley Periodicals LLC.
Références
Ashkenazi-Preiser, H., Mikula, I., & Baniyash, M. (2021). The diverse roles of myeloid derived suppressor cells in mucosal immunity. Cellular Immunology, 365, 104361. doi: 10.1016/j.cellimm.2021.104361
Ben-Meir, K., Twaik, N., & Baniyash, M. (2018). Plasticity and biological diversity of myeloid derived suppressor cells. Current Opinion in Immunology, 51, 154-161. doi: 10.1016/j.coi.2018.03.015
Ben-Meir, K., Twaik, N., Meirow, Y., & Baniyash, M. (2022). An in vivo mouse model for chronic inflammation-induced immune suppression: A “factory” for myeloid-derived suppressor cells (MDSCs). Current Protocols, 2, e558. doi: 10.1002/cpz1.558
Donovan, J., & Brown, P. (2005). Euthanasia. Current Protocols in Neuroscience, 33, A.4H.1-A.4H.4. doi: 10.1002/0471142301.nsa04hs33
Hou, A., Hou, K., Huang, Q., Lei, Y., & Chen, W. (2020). Targeting myeloid-derived suppressor cell, a promising strategy to overcome resistance to immune checkpoint inhibitors. Frontiers in Immunology, 11, 783. doi: 10.3389/fimmu.2020.00783
Meirow, Y., Jovanovic, M., Zur, Y., Habib, J., Colombo, D. F., Twaik, N., … Baniyash, M. (2022). Specific inflammatory osteoclast precursors induced during chronic inflammation give rise to highly active osteoclasts associated with inflammatory bone loss. Bone Research, 10, 36. doi: 10.1038/s41413-022-00206-z
Reuven, O., Mikula, I., Jr., Ashkenazi-Preiser, H., Twaik, N., Ben-Meir, K., Meirow, Y., … Baniyash, M. (2022). Functional assays evaluating immunosuppression mediated by myeloid-derived suppressor cells. Current Protocols, 2, e557. doi: 10.1002/cpz1/557
Sade-Feldman, M., Kanterman, J., Ish-Shalom, E., Elnekave, M., Horwitz, E., & Baniyash, M. (2013). Tumor necrosis factor-α blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. Immunity, 38, 541-554. doi: 10.1016/j.immuni.2013.02.007
Sade-Feldman, M., Kanterman, J., Klieger, Y., Ish-Shalom, E., Olga, M., Saragovi, A., … Baniyash, M. (2016). Clinical significance of circulating CD33+CD11b+HLA-DR− myeloid cells in patients with stage IV melanoma treated with ipilimumab. Clinical Cancer Research, 22, 5661-5672. doi: 10.1158/1078-0432.CCR-15-3104